Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Mar;37(3):532–539. doi: 10.1128/aac.37.3.532

Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.

E Connor 1, S Morrison 1, J Lane 1, J Oleske 1, R L Sonke 1, J Connor 1
PMCID: PMC187703  PMID: 8460922

Abstract

Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic evaluations. The children tolerated the drug well, and treatment was not associated with any clinically significant adverse effects. Peak concentrations in plasma of 2.5 and 3.0 microM were reached at 90 min after single oral doses of 6 and 10 mg/kg, respectively. The mean systemic availability of oral ribavirin was 42.3%. After 60 days of ribavirin administration, mean trough concentrations in plasma of 2.6 and 4.1 microM were obtained. Ribavirin penetrated well into the cerebrospinal fluid, achieving 70% of the concentration in plasma at steady state.

Full text

PDF
532

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin R. K., Trefts P. E., Hintz M., Connor J. D., Kagnoff M. F. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob Agents Chemother. 1983 Nov;24(5):696–701. doi: 10.1128/aac.24.5.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baba M., Pauwels R., Balzarini J., Herdewijn P., De Clercq E., Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 1987 Oct;31(10):1613–1617. doi: 10.1128/aac.31.10.1613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Balzarini J., Herdewijn P., De Clercq E. Potentiating effect of ribavirin on the anti-retrovirus activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside in vitro and in vivo. Antiviral Res. 1989 May-Jun;11(4):161–171. doi: 10.1016/0166-3542(89)90001-6. [DOI] [PubMed] [Google Scholar]
  4. Balzarini J., Naesens L., Robins M. J., De Clercq E. Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside. J Acquir Immune Defic Syndr. 1990;3(12):1140–1147. [PubMed] [Google Scholar]
  5. Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
  6. Chandwani S., Borkowsky W., Krasinski K., Lawrence R., Welliver R. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr. 1990 Aug;117(2 Pt 1):251–254. doi: 10.1016/s0022-3476(05)80539-6. [DOI] [PubMed] [Google Scholar]
  7. Crumpacker C., Bubley G., Lucey D., Hussey S., Connor J. Ribavirin enters cerebrospinal fluid. Lancet. 1986 Jul 5;2(8497):45–46. doi: 10.1016/s0140-6736(86)92590-0. [DOI] [PubMed] [Google Scholar]
  8. Crumpacker C., Heagy W., Bubley G., Monroe J. E., Finberg R., Hussey S., Schnipper L., Lucey D., Lee T. H., McLane M. F. Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient clinical improvement associated with suppression of the human immunodeficiency virus and enhanced lymphocyte proliferation. Ann Intern Med. 1987 Nov;107(5):664–674. doi: 10.7326/0003-4819-107-5-664. [DOI] [PubMed] [Google Scholar]
  9. Fernandez-Larsson R., Patterson J. L. Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase. Mol Pharmacol. 1990 Dec;38(6):766–770. [PubMed] [Google Scholar]
  10. Gilbert B. E., Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 1986 Aug;30(2):201–205. doi: 10.1128/aac.30.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hall C. B., McBride J. T., Walsh E. E., Bell D. M., Gala C. L., Hildreth S., Ten Eyck L. G., Hall W. J. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983 Jun 16;308(24):1443–1447. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
  12. Knight V., McClung H. W., Wilson S. Z., Waters B. K., Quarles J. M., Cameron R. W., Greggs S. E., Zerwas J. M., Couch R. B. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981 Oct 31;2(8253):945–949. doi: 10.1016/s0140-6736(81)91152-1. [DOI] [PubMed] [Google Scholar]
  13. Krasinski K., Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA. 1989 May 5;261(17):2512–2516. [PubMed] [Google Scholar]
  14. Laskin O. L., Longstreth J. A., Hart C. C., Scavuzzo D., Kalman C. M., Connor J. D., Roberts R. B. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1987 May;41(5):546–555. doi: 10.1038/clpt.1987.70. [DOI] [PubMed] [Google Scholar]
  15. Lertora J. J., Rege A. B., Lacour J. T., Ferencz N., George W. J., VanDyke R. B., Agrawal K. C., Hyslop N. E., Jr Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1991 Oct;50(4):442–449. doi: 10.1038/clpt.1991.162. [DOI] [PubMed] [Google Scholar]
  16. Markowitz L. E., Chandler F. W., Roldan E. O., Saldana M. J., Roach K. C., Hutchins S. S., Preblud S. R., Mitchell C. D., Scott G. B. Fatal measles pneumonia without rash in a child with AIDS. J Infect Dis. 1988 Aug;158(2):480–483. doi: 10.1093/infdis/158.2.480. [DOI] [PubMed] [Google Scholar]
  17. McCormick J. B., Getchell J. P., Mitchell S. W., Hicks D. R. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet. 1984 Dec 15;2(8416):1367–1369. doi: 10.1016/s0140-6736(84)92060-9. [DOI] [PubMed] [Google Scholar]
  18. McCormick J. B., King I. J., Webb P. A., Scribner C. L., Craven R. B., Johnson K. M., Elliott L. H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986 Jan 2;314(1):20–26. doi: 10.1056/NEJM198601023140104. [DOI] [PubMed] [Google Scholar]
  19. Ogle J. W., Toltzis P., Parker W. D., Alvarez N., McIntosh K., Levin M. J., Lauer B. A. Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis. 1989 Apr;159(4):748–750. doi: 10.1093/infdis/159.4.748. [DOI] [PubMed] [Google Scholar]
  20. Page T., Connor J. D. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem. 1990;22(4):379–383. doi: 10.1016/0020-711x(90)90140-x. [DOI] [PubMed] [Google Scholar]
  21. Patterson J. L., Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis. 1990 Nov-Dec;12(6):1139–1146. doi: 10.1093/clinids/12.6.1139. [DOI] [PubMed] [Google Scholar]
  22. Powers C. N., Peavy D. L., Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob Agents Chemother. 1982 Jul;22(1):108–114. doi: 10.1128/aac.22.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ray C. G., Icenogle T. B., Minnich L. L., Copeland J. G., Grogan T. M. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis. 1989 May;159(5):829–836. doi: 10.1093/infdis/159.5.829. [DOI] [PubMed] [Google Scholar]
  24. Roberts R. B., Dickinson G. M., Heseltine P. N., Leedom J. M., Mansell P. W., Rodriguez S., Johnson K. M., Lubina J. A., Makuch R. W. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. J Acquir Immune Defic Syndr. 1990;3(9):884–892. [PubMed] [Google Scholar]
  25. Roberts R. B., Hollinger F. B., Parks W. P., Rasheed S., Laurence J., Heseltine P. N., Makuch R. W., Lubina J. A., Johnson K. M. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group. AIDS. 1990 Jan;4(1):67–72. doi: 10.1097/00002030-199001000-00009. [DOI] [PubMed] [Google Scholar]
  26. Roberts R. B., Laskin O. L., Laurence J., Scavuzzo D., Murray H. W., Kim Y. T., Connor J. D. Ribavirin pharmacodynamics in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1987 Oct;42(4):365–373. doi: 10.1038/clpt.1987.165. [DOI] [PubMed] [Google Scholar]
  27. Ross L. A., Kim K. S., Mason W. H., Jr, Gomperts E. Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. Am J Med. 1990 Mar;88(3):313–314. doi: 10.1016/0002-9343(90)90162-7. [DOI] [PubMed] [Google Scholar]
  28. Schulof R. S., Parenti D. M., Simon G. L., Paxton H., Meyer W. A., 3rd, Schlesselman S. B., Courtless J., LeLacheur S., Sztein M. B. Clinical, virologic, and immunologic effects of combination therapy with ribavirin and isoprinosine in HIV-infected homosexual men. J Acquir Immune Defic Syndr. 1990;3(5):485–492. [PubMed] [Google Scholar]
  29. Sension M. G., Quinn T. C., Markowitz L. E., Linnan M. J., Jones T. S., Francis H. L., Nzilambi N., Duma M. N., Ryder R. W. Measles in hospitalized African children with human immunodeficiency virus. Am J Dis Child. 1988 Dec;142(12):1271–1272. doi: 10.1001/archpedi.1988.02150120025021. [DOI] [PubMed] [Google Scholar]
  30. Sharer L. R., Dowling P. C., Michaels J., Cook S. D., Menonna J., Blumberg B. M., Epstein L. G. Spinal cord disease in children with HIV-1 infection: a combined molecular biological and neuropathological study. Neuropathol Appl Neurobiol. 1990 Aug;16(4):317–331. doi: 10.1111/j.1365-2990.1990.tb01266.x. [DOI] [PubMed] [Google Scholar]
  31. Spector S. A., Kennedy C., McCutchan J. A., Bozzette S. A., Straube R. G., Connor J. D., Richman D. D. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. J Infect Dis. 1989 May;159(5):822–828. doi: 10.1093/infdis/159.5.822. [DOI] [PubMed] [Google Scholar]
  32. Vogt M. W., Hartshorn K. L., Furman P. A., Chou T. C., Fyfe J. A., Coleman L. A., Crumpacker C., Schooley R. T., Hirsch M. S. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science. 1987 Mar 13;235(4794):1376–1379. doi: 10.1126/science.2435003. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES